Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review)

xlomafota13 shared this article with you from Inoreader Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1267. doi: 10.3892/etm.2021.10702. Epub 2021 Sep 7. ABSTRACT Peritoneal carcinomatosis, as well as the presence of liver metastases from colorectal cancer, has been long considered as the sign of a systemic disease, transforming the patient into a candidate for palliation and best supportive care. However, in recent decades, progress in the field of medical and surgical oncology has allowed scientists worldwide to produce curative therapeutic strategies for these cases such as hyperthermic intraperitoneal chemotherapy (HIPEC) or extended liver resection. In addition, the association of these two therapies has also been performed with encouraging results. The aim of the current study was to review articles published thus far in regard to the association of these two therapeutic strategies, in order to identify which cases can benefit the most, which is the most efficient agent or combination of agents, and w hether these types of therapy should be performed as monotherapy or as a two-stage procedure. PMID:34594404 | PMC:PMC8456510 | DOI:10.3892/etm.2021.10702 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.